Trial · NCT01799590
Results by group108
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 108
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events | Placebo/Topiramate (JNS019) | 110 | Participants | ||
| Number of Participants With Adverse Events | Topiramate (JNS019) 50 mg | 85 | Participants | ||
| Number of Participants With Adverse Events | Topiramate (JNS019) 100 mg | 79 | Participants | ||
| Change From Baseline in the Number of Monthly Migraine Attacks as Per 24-hour Rule in the Continuous Treatment Period | Placebo/Topiramate (JNS019) | Baseline (28 days before randomization) | 6.5 | Standard Deviation 2.27 | Migraine attacks |
| Change From Baseline in the Number of Monthly Migraine Attacks as Per 24-hour Rule in the Continuous Treatment Period | Topiramate (JNS019) 50 mg | Baseline (28 days before randomization) | 5.9 | Standard Deviation 1.76 | Migraine attacks |
| Change From Baseline in the Number of Monthly Migraine Attacks as Per 24-hour Rule in the Continuous Treatment Period | Topiramate (JNS019) 100 mg | Baseline (28 days before randomization) | 6.0 | Standard Deviation 1.91 | Migraine attacks |
| Change From Baseline in the Number of Monthly Migraine Attacks as Per 24-hour Rule in the Continuous Treatment Period | Placebo/Topiramate (JNS019) | Change during Continuous treatment period | -2.1 | Standard Deviation 2.47 | Migraine attacks |
| Change From Baseline in the Number of Monthly Migraine Attacks as Per 24-hour Rule in the Continuous Treatment Period | Topiramate (JNS019) 50 mg | Change during Continuous treatment period | -1.0 | Standard Deviation 3.21 | Migraine attacks |
| Change From Baseline in the Number of Monthly Migraine Attacks as Per 24-hour Rule in the Continuous Treatment Period | Topiramate (JNS019) 100 mg | Change during Continuous treatment period | -1.6 | Standard Deviation 2.11 | Migraine attacks |
| Change From Baseline in the Average Number of Monthly Migraine Attack Days in Continuous Treatment Period | Placebo/Topiramate (JNS019) | Baseline (28 days before randomization) | 7.3 | Standard Deviation 2.56 | Days |
| Change From Baseline in the Average Number of Monthly Migraine Attack Days in Continuous Treatment Period | Topiramate (JNS019) 50 mg | Baseline (28 days before randomization) | 6.5 | Standard Deviation 2.09 | Days |
| Change From Baseline in the Average Number of Monthly Migraine Attack Days in Continuous Treatment Period | Topiramate (JNS019) 100 mg | Baseline (28 days before randomization) | 6.7 | Standard Deviation 2.16 | Days |
| Change From Baseline in the Average Number of Monthly Migraine Attack Days in Continuous Treatment Period | Placebo/Topiramate (JNS019) | Change during Continuous treatment period | -2.4 | Standard Deviation 2.78 | Days |
| Change From Baseline in the Average Number of Monthly Migraine Attack Days in Continuous Treatment Period | Topiramate (JNS019) 50 mg | Change during Continuous treatment period | -1.1 | Standard Deviation 3.24 | Days |
| Change From Baseline in the Average Number of Monthly Migraine Attack Days in Continuous Treatment Period | Topiramate (JNS019) 100 mg | Change during Continuous treatment period | -1.9 | Standard Deviation 2.44 | Days |
| Change From Baseline in the Average Number of Monthly Headache Days in Continuous Treatment Period | Placebo/Topiramate (JNS019) | Baseline (28 days before randomization) | 7.5 | Standard Deviation 2.73 | Days |
| Change From Baseline in the Average Number of Monthly Headache Days in Continuous Treatment Period | Topiramate (JNS019) 50 mg | Baseline (28 days before randomization) | 6.8 | Standard Deviation 2.07 | Days |
| Change From Baseline in the Average Number of Monthly Headache Days in Continuous Treatment Period | Topiramate (JNS019) 100 mg | Baseline (28 days before randomization) | 7.2 | Standard Deviation 2.36 | Days |
| Change From Baseline in the Average Number of Monthly Headache Days in Continuous Treatment Period | Placebo/Topiramate (JNS019) | Change during Continuous treatment period | -2.6 | Standard Deviation 2.75 | Days |
| Change From Baseline in the Average Number of Monthly Headache Days in Continuous Treatment Period | Topiramate (JNS019) 50 mg | Change during Continuous treatment period | -1.2 | Standard Deviation 3.28 | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01799590/results